HydrogenPro (OSE: HYPRO) meets the European Hydrogen Bank regulations

Navamedic Q3 2024: Business remains strong in quarter impacted by cyclical nature of the business

Oslo, 31 October 2024 – In the third quarter of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 123.1 million…

Navamedic Q2 och H1 2024: Den stabila tillväxten fortsätter och stöds av ett nytt licensavtal

Oslo, 16 augusti 2024 – Under första halvåret 2024 levererade Navamedic ASA (OSE: NAVA), ett nordiskt läkemedelsföretag och leverantör av produkter till sjukhus och apotek, en omsättning på 277,2 miljoner NOK, en ökning…

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement

Oslo, 16 August 2024 – In first half of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 277.2 million, up 12.…

Navamedic ASA: Broad launch for Eroxon® in Sweden today

Oslo, 6 May 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies has launched Eroxon® in Sweden. Eroxon® is clinically proven and considered…

Japanska gummiterminer handlas till den högsta prisnivån på 13 år

Japanska gummiterminer steg för den nionde sessionen i rad under fredagen och handlades under dagen på den högsta nivån på 13 år. Viktiga producerande länder har väderproblem. Osaka Exchange (OSE) gummikontrakt för le…

Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives

  Oslo, 15 February 2024 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the ful…

Navamedic ASA: Renewed contract signed with Vitaflo International Limited

Oslo, 21 December 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces it has renewed its contract with Vitaflo Internation…

Smartoptics Group AS (SMOP) – Q3 2023 financial results

Oslo, 8 November 2023 - Smartoptics Group AS (Smartoptics, OSE: SMOP) today reported revenues of USD 13.6 million in the third quarter of 2023 (13.5), and an underlying growth of 13% when excluding 5G related projects.

Navamedic ASA: Record high quarter with above 50 percent growth

Oslo, 1 November 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the third quarter of 2023. With growt…

Smartoptics Group AS (SMOP) – Q2 2023: Continued strong growth and solid margins.

Oslo, 23 August 2023 - Smartoptics Group AS (OSE: SMOP) today reported revenues of USD 17.0 million in the second quarter of 2023, up 16.3 percent from the corresponding period in 2022 (USD 14.

Navamedic ASA: Significant growth across the business

Oslo, 11 August 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the second quarter and first half of 2…

Navamedic ASA Q1 2023: Another strong quarter

Oslo, 11 May 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the first quarter of 2023. Navamedic expe…

Smartoptics Group AS (SMOP) – Q1 2023: Continued strong growth and increased margins

Oslo, May 11, 2023 - Smartoptics Group AS (OSE: SMOP) today reported revenues of USD 14.1 million in the first quarter of 2023, up 18.8 percent from the corresponding period in 2022 (USD 11.

OKEA ASA – NOK 1.00 dividend payment payable on or about 15 June

(Trondheim, 4 May 2023) - OKEA ASA (OSE: OKEA): On 12 May 2022 the annual general meeting of OKEA granted the board of directors an authorisation to approve distribution of dividends based on the company's annual account…

Navamedic ASA: Annual Report for 2022

Oslo, 28 April 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, announce that the company has published its Annual Report for 2022, whi…

Navamedic ASA: Recommended cash offer to acquire Sensidose for approximately SEK 75 million

Oslo, 29 March 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and provider of high-quality products to hospitals and pharmacies, has today submitted a cash offer to acquire all shares in Sensidose AB (“Sensido…

Lokförarfack: Brist i säkerhetssystem

Enligt de grekiska lokförarnas fackförbund hade nattens allvarliga tågolycka kunnat undvikas "om säkerhetssystemen hade fungerat". Enligt Kostas Genidounias, ordförande för fackförbundet OSE, är nattens olycka "ofattbar"…

Smartoptics Group AS (SMOP) – Q4 2022: Strong growth and high margins

Oslo, 17 February 2022 - Smartoptics Group AS (OSE: SMOP) today reported revenues of USD 18.1 million in the fourth quarter of 2022, up 45.2 percent from the corresponding period in 2021 (USD 12.

Navamedic ASA: Q4 2022 financial results

Oslo, 16 February 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the fourth quarter of 2022. In the p…

Axel Johnson-ägda solcellsbolaget Otovo till Oslobörsens huvudlista

Efter ett rekordår för solenergimarknaden tar nu Otovo klivet upp till Oslobörsens huvudlista OSE.

Saga Pure: Contemplating establishment and subsequent listing of new investment company

(Oslo, 9 November 2022) Saga Pure ASA (Saga Pure, OSE: SAGA) today announces the intention to establish a new industrial investment company focused on distressed assets, with the ambition of a separate listing on Euronex…

Smartoptics Group AS (SMOP) – Q3 2022 financial results

Oslo, 26 October 2022 – Smartoptics Group AS (OSE: SMOP) today reported revenues of USD 13.6 million in the third quarter of 2022, up 23.0% from the corresponding period in 2021 (11.

Updated: Smartoptics Group AS (SMOP) – Q2 2022 financial results

Oslo, 10 August 2022 - Smartoptics Group AS (Smartoptics, OSE: SMOP) today reported revenues of USD 14.6 million in the second quarter of 2022, up 18.1% from the corresponding period in 2021 (12.

Smartoptics Group AS (SMOP) – Q2 2022 financial results

Oslo, 10 August 2022 - Smartoptics Group AS (Smartoptics, OSE: SMOP) today reported revenues of USD 14.6 million in the second quarter of 2022, up 18.1% from the corresponding period in 2021 (12.

Immunicum och PCI Biotech tillkännager förlängning av sitt forskningssamarbete med att utforska nya behandlingar med cancervaccin

Pressmeddelande  Stockholm 30 november, 2021 Immunicum och PCI Biotech tillkännager förlängning av sitt forskningssamarbete med att utforska nya behandlingar med cancervaccin Immunicum AB (publ; IMMU.ST), ett bi…